1 Erratum to: Clin Drug Investig (2013) 33:761–771 DOI 10.1007/s40261-013-0126-5
Page 771, Reference 11, which previously read:
Bakish D, Gommoll C, Chen C, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study Int Clin Psychopharmacol. 2013 (in press).
Should read:
Bakish D, Bose A, Gommoll C, Chen C, Greenberg WM, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2013: doi: 10.11503/jpn.130040 (In Press)
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40261-013-0126-5.
Rights and permissions
About this article
Cite this article
Mago, R., Forero, G., Greenberg, W.M. et al. Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study. Clin Drug Investig 33, 861 (2013). https://doi.org/10.1007/s40261-013-0133-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-013-0133-6